QuantHealth, a pioneering AI-powered clinical trial design company, has reached a milestone with over 100 successful simulated trials. This achievement marks a significant advancement in drug development, enabling design teams to address the prevalent issue of trial failures.
QuantHealth’s Clinical Simulator harnesses advanced analytics and patient-centric solutions to forecast individual patient responses within trials. This technology allows for real-time adjustments to trial strategies, ensuring optimal design and increased efficiency.
QuantHealth has demonstrated its impact in a partnership with a pharmaceutical company specializing in respiratory diseases. By simulating over 5,000 protocol variations using patient and drug entity data, the company identified key factors contributing to trial success. The optimized protocol reduced study duration by 11 months, decreased clinical subject enrollment by 251, and lowered full-time employee requirements by 1.5, resulting in substantial financial savings.
QuantHealth’s accuracy outcomes are superior to national averages for Phase II and III trials, highlighting the power of AI in clinical research. The company employs a rigorous validation process to ensure the reliability of its simulations.
QuantHealth empowers trial design teams to make informed decisions by providing preemptive insights into trial dynamics. This predictive capability reduces setbacks and paves the way for enhanced outcomes.
By leveraging AI, QuantHealth addresses the core issue of trial failures at scale, enabling pharmaceutical companies to develop drugs more efficiently and effectively. With partnerships with five of the top 20 pharmaceutical companies and expectations to double that number in the coming year, QuantHealth plays a pivotal role in transforming drug development.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
